Service Hotline +86 400-068-7188

China Blood Products Industry Production & Marketing Demand and Investment Forecast Report, 2013-2017

China Blood Products Industry Production & Marketing Demand and Investment Forecast Report, 2013-2017

China Blood Products Industry Production & Marketing Demand and Investment Forecast Report, 2013-2017

A must-have for enterprise medium to long-term strategic planning

Without deep industry knowledge, it will be difficult to gain any return

English Version:USD7900

Including: Paper back + Electronic Copy + Invoice

Customer Hotline:+86 755 - 82925195 / 82925295

Free Hotline:+86 400-068-7188After-sales Hotline: +86 755-33013088

The Ministry of Commerce of the People's Republic of China designated Qianzhan Industrial Research Institute as the only "regional workstation for dealing with trade friction" in the Guangdong-Hong Kong-Macao Greater Bay Area

Special Statement

We are aware of that the content of our products have been stolen by some ones who changed the design and used it to deceive customers as it is their own products. Customers who are misled may experience no product received or an incomplete product. Therefore, Qianzhan Industrial Research Institute encourage you to arrange an in-person visit to our company before you make the purchase. Qianzhan has the sole copyright of all research reports. We have never had partnership or affiliated with any third party agent. Please recognize the"前瞻"trademark when purchasing reports.To have better investment return or strategic outcomes, you must have a forward-looking vision. Qianzhan Industrial Research Institute - China's leading industry consulting institutions provide you with all the things you need in business!

* The table of contents and the rest of this report are originally created by Qianzhan. Without any prior written permission, it is prohibited to copy or reproduce in any way. To have better investment return or strategic outcomes, you must have a forward-looking vision!

  • Table of Contents

  • Content Summary

China Blood Products Industry Production & Marketing Demand and Investment Forecast Report, 2013-2017

Reporting core values

The most distinctive characteristics of this report is forward-looking and timeliness. Through analyzing forward-looking characteristic of abundant first-hand market data, we deeply and objectively dissect China current blood products industry’s overall market capacity, market size, competitive landscape and characteristics of market demand. Furthermore, based on future development tracks and years’ practice experience of blood products industry, we conduct prudent analysis and forecast for blood products industry’s future development trend.

Main Contents of report

At present, there are 32 blood products enterprises with production license, among which 20 of them can normally maintain their operational activities, and the industry concentration is relatively high. Benefited from the advancement of economic level and technologies, the acceleration of population growth and population aging, as well as other factors, the blood products industry is now in a preferential development period. Since 2005, the blood products market has shown the high prosperity of demand and supply, while the demand growth speed is faster than that of supply. In recent years, the market size of blood products industry maintains the high-speed growth. During the “eleventh five-year” period, the growth rate of industry sales revenue was generally above 11%, far higher that that of the international blood products industry over the same period. In 2010, the invested blood plasma amount reached around 3,600 tons, and the industry sales revenue reached nearly 9 billion Yuan.

The year of 2011 was the fist year of “twelfth five-year” period. with the support of officially implementation of biology industry regulation and new edition of GMP standard, the blood products will definitely meet a new opportunity. In the long-term, the supply of blood products is not sufficient; the industry maintains high prosperity; and the terminal products demand will be split apart. Albumin and IVIG will rapidly tend to a balance of demand and supply. It’s predicted the growth rate will slow down after 2012, and it will enter a steady growth period; while the small products, like the blood clotting factors will continue to grow rapidly, and t he blood clotting factors may completely be a major variety like albumin in the future.

Similar to the development trend of international industry, the concentration of domestic blood products industry keeps improving. Compared to foreign industries, the concentration of China current blood products industry is obviously low. The invested blood amount of domestic first class of enterprises is generally about 300-500 tons, which is far part from the 1200 tons of foreign blood products giants. And there is still vast space for enterprises’ merger and consolidation.

At present, China blood products enterprises can be mainly divided into 3 parts: the first part is represented by Hualan Biological, Shanghai RAAS, and Tiantan Biological; the second part is represented by 4-10 blood plasma stations, with simple production line, but they are also the monopolized enterprise in blood plasma source in their regions; and the third part is represented by more than 10 enterprises have neither advantages of production line and blood plasma station. According to the regulation from the Ministry of Public Health, the small and medium-sized enterprise with less than 6 kinds of products can not build blood plasma station, so it’s predicted that the first part of enterprises can keep expanding by gaining capital relying on their own scale advantage and from the capital market. However, due to the monopoly of blood plasma station in a region (it’s not allowed to build 2 or more blood plasma stations in one region, and it’s not allowed to collect blood plasma across regions), there are less and less new blood plasma stations in the undeveloped economic areas of central and western regions. Therefore, once the second and third class of blood products enterprises have blood plasma stations with simple product structure, they will be purchased, and the third class of enterprises with fewer advantages will gradually be cleaned out.

Blood plasma is the lifeline of blood products industry. If the blood products enterprises lack of blood plasma, the enterprises will lose the lifeline what they depend on. Therefore, the standardized management of blood plasma stations will be beneficial for assuring the safety of China blood products. With the increasing of new-built blood plasma stations, the leading enterprises emerge in the industry, such as Hualan Biological, Shanghai RAAS and Yuanda Shuyang Pharmaceutical, which gradually expand their size. The industry level tends to more and more normalized. There will be more and more required products in the market. In addition, the price of blood products is generally more expensive than other medicines. Except for blood clotting factors, the consumption volume of albumin and IVIG will far lower than that of developed countries. With the economy development and the improvement of people’s living standard, the healthcare security system keeps to be improved. The blood products have been concluded into the Ssope of medicine reimbursement. With the improving recognition of blood products for doctors and patients, as well as the advancement of clinical treatment methods, China blood products market has vast space for development.

The report mainly analyzes the development overview of China blood products industry; the development situation and import/export market of blood products industry; the competitive landscape of blood products industry; the market analysis of blood products industry; the leading corporations’ operational conditions in blood products industry; as well as the investment and development forecast of blood products industry. Meanwhile, with comprehensive and specific first-hand market data over the past 5 years, Forward helps you to grasp the market and development trends of blood products industry, so as to win advantages from competition!

The most distinctive characteristics of this report is forward-looking and timeliness. Through analyzing forward-looking characteristic of abundant first-hand market data, we deeply and objectively dissect China current blood products industry’s overall market capacity, market size, competitive landscape and characteristics of market demand. Furthermore, based on future development tracks and years’ practice experience of blood products industry, we conduct prudent analysis and forecast for blood products industry’s future development trend. This report helps blood products manufacturing enterprises, R&D institutions, marketing enterprises and investment enterprises to precisely grasp current latest developments of the industry. Afterwards, they can make wise operating decisions and define enterprises’ development directions.

Here, we would like to express our sincere gratitude to State Information Center, Bureau of Statistics of China, China Customs, International Information Research Institute, Chinese Academy of International Trade and Economic Cooperation, Tsinghua University Library, Development Research Center of the State Council and Beijing Essence Forward Research Center, for their great support when we conduct this report!

Notice: All the market data, especially corporations' ranking data in the report, only for business reference. Please do not take the data for enterprise publicity. Thank you! Or Forward shall not take any responsibility for any consequences!

Qianzhan Business Information Co., Ltd. Industry Research Center
Research Team of Blood Products Industry

For any special needs, please contact us.Customize Your Report

  • The National Bureau of Statistics Foreign-related investigation Permission

  • National Innovation Company and Dual Software Certified Enterprise

  • The only DRC desginated Enterprise of the Industry Yearbook

  • National Ministry of Commerce designated Industrial Early Warning and Monitoring Workstation

  • Guangdong Province Enterprise of Observing Contract and Valuing Credit

Qianzhan Industrial Research Institute· The leading company of China Business Consulting

  • 01

    Qianzhan is an industry consulting service provider with national innovation company qualification, independent research and development of industrial big data and Dual Software Certification.

  • 02

    Qianzhan is a consulting and research organization that has been engaged in business consulting for over 16 years in China.

  • 03

    Qianzhan is a consulting service provider with a team of nearly 300 industrial researchers and analysts.

  • 04

    Qianzhan is a consulting service provider with an in-house expert pool of 1200 experts.

  • 05

    Qianzhan is a research and consulting organization that have served 180000 clients and received over positive comments from 100000 of our clients.

  • 06

    Qianzhan is an industry research and consulting organization that has been designated by the highest authority, the DRC, to prepare the yearbook.

  • 07

    Qianzhan is an industry planning and consulting organization that adopts the internationally synchronized SCP scientific analysis model and the perfect industry chain research map to guide the business planning and consulting.

  • 08

    Qizhan is a consulting service organization that helps enterprises to solve the five aspects of industry research, planning, strategic design, capital operation and implementation.

What Else do We Offer

Contact Us

Shenzhen Headquarter

Free Hotline:+86 400-068-7188

Customer Hotline:+86 755 - 82925195 / 82925295

Email Address:service@qianzhan.com

3rd Floor, FIYTA Building West, High Tech South Avenue 1, Nanshan District, Shenzhen, China

Shanghai Office

Location:Rm.1106, Building 1, Jiayu International Plaza, Songhu Road, Yangpu District,
Shanghai, China